Extending private runways

While the private biotech sector is seeing a serious influx of new venture capital, investors say not to expect a corresponding increase in the amount of new company formations.

According to BioCentury’s BCIQ database, since the start of 2015, VCs who invest in life sciences have raised more than $21.1 billion in at least 69 funds, including at least $14.7 billion earmarked for therapeutics, diagnostics and medical devices...